Precigen: Positive Phase 1 Data for Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy

 Repeated administrations of PRGN-2012 were well-tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2 –

–  Clinical data show strong response in RRP patients with 50% of patients in Complete Response, requiring no post-treatment surgeries, following PRGN-2012 treatment at Dose Level 2; All complete responders remain surgery-free post-treatment with a minimum follow up of 12 months –

–  PRGN-2012 treatment at Dose Level 2 significantly reduced the need for surgeries in severe, aggressive RRP patients; Median number of RRP surgeries in 12-month period reduced from 6.5 pre-treatment to 0.5 post-treatment –

–  Phase 2 study is enrolling patients with a total of 32 patients enrolled at Dose Level 2 to date –

–  Company to outline regulatory strategy in RRP as US Food and Drug Administration (FDA) discussions advance –

–  Precigen to host R&D Day virtual event today at 4:30 PM ET –

The company will host an R&D Day virtual event today at 4:30 PM ET to showcase the data and will feature presentations by Clint T. Allen, MD, Senior Investigator, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute (NCI) and lead associate investigator for the PRGN-2012 clinical trial, and Precigen's President and CEO, Helen Sabzevari, PhD. Participants may register and access the live webcast through Precigen's investor relations website in the Events & Presentations section.

https://finance.yahoo.com/news/precigen-announces-positive-phase-1-210100062.html